Company Overview - Intelligent Bio Solutions Inc. (INBS) has secured a key patent in the United States for its Intelligent Fingerprinting Drug Screening Cartridge, marking its sixth active patent in the U.S. [1][4] - The company aims to enhance its competitive edge and accelerate the commercialization of its technology as it approaches market launch [2][4]. Market Position and Financials - INBS currently has a market capitalization of 1.67, with a 6-month decline of 8.2%, compared to the industry's 13.2% decline [3]. Product and Technology - The Intelligent Fingerprinting Drug Screening Cartridge is a non-invasive drug testing solution that detects drug metabolites through fingerprint sweat analysis, offering rapid and hygienic screening [9][10]. - The cartridge collects a small sweat sample and provides results in minutes, eliminating the need for invasive sample collection and reducing contamination risks [10]. Intellectual Property and Competitive Advantage - INBS has developed a robust intellectual property portfolio, with six active U.S. patents covering various aspects of its drug screening technology [6][8]. - The strengthened IP protection reduces imitation risks and reinforces investor confidence in the company's long-term growth potential [4]. Industry Prospects - The global drug screening market was valued at 19.5 billion by 2029, positioning INBS to capitalize on this growth with its patented technology [11].
Intelligent Bio Solutions Stock Drops Despite Key U.S. Patent Win